Amgen announces retirement of CTO and other executive changes

Amgen (AMGN) announced the retirement of David M. Reese, M.D., EVP and Chief Technology Officer, effective June 30. Reese joined Amgen in 2005 as a clinical development leader in oncology and later served as executive vice president of R&D from 2018 to 2023. Amgen is making the following changes effective June 1, 2026: James Bradner will serve as EVP, R&D, Artificial Intelligence and Data. Sean Bruich will serve as SVP, CTO. Murdo Gordon will serve as EVP, Amgen Global Markets and Policy, which includes Medical, Commercial Operations, Government Affairs and Policy. Paul Burton will continue to serve as SVP, Chief Medical Officer.